There’s new evidence that the dominant approach to Alzheimer’s may be completely wrong [MarketWatch]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: MarketWatch
There’s new evidence that the dominant approach to Alzheimer’s may be completely wrong A closely watched Alzheimer’s study that tested out a major scientific theory of the disease has left some experts questioning the entire approach. Many drugmakers, including Biogen BIIB, -0.72% and Eisai 4523, -0.42% which were responsible for last month’s trial , designed their approach around a decades-old theory of the degenerative disease. But there hasn’t been a lot to show for it, including a number of recent high-profile drug failures. And recent results from a phase 2 trial of Biogen and Eisai’s Alzheimer’s drug BAN2401, though ostensibly positive, may not change the larger picture. Two leading experts are even more dubious about the tilt of Alzheimer’s drug development after the BAN2401 results , according to a new report from Leerink Partners analyst Geoffrey Porges. They saw “little to no evidence of activity” for BAN2401, and the outcome “reduced their already low confidence in th
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- American College Of Physicians Officially Recommends GLP-1s Like Ozempic For Diabetes Treatment—Despite Shortage Concerns [Forbes]Forbes
- Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data [Yahoo! Finance]Yahoo! Finance
- Corticosteroids Market Size Expected to Reach USD 6.91 Bn by 2033 [Yahoo! Finance]Yahoo! Finance
- As Zepbound shortage grows, Eli Lilly says there's no immediate end in sight [MSNBC.com]MSNBC.com
- The Zacks Analyst Blog Highlights Eli Lilly, Linde, Caterpillar, Salesforce, and Wells Fargo [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/6/24 - Miss
LLY
Sec Filings
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- LLY's page on the SEC website